3 Food Recalls You Need To Know About This Week
It's not every week that we report on contaminated food and faulty appliances that have led to hospitalizations and property damage. Find out why microwaveable chicken fettuccine Alfredo meals, mini fridges, and chocolate-covered almonds are under fire this week.
On June 17, FreshRealm recalled its chicken fettuccine Alfredo products after an ongoing investigation revealed that this item is likely linked to an outbreak strain of listeria monocytogenes.
The USDA's Food Safety and Inspection Service (FSIS) began exploring this link on March 19, after routine sampling detected the food pathogen.
The CDC reports that there have been 17 confirmed cases of listeriosis, but that the number of sick people is likely higher. (People who recover without going to the doctor aren't tested for listeria.) Three people died after eating food contaminated with listeria.
The now-recalled ready-to-eat meals were sold nationwide at Kroger and Walmart locations under brand names Marketside and Home Chef.Products: Marketside Grilled Chicken Alfredo with Fettuccine and Home Chef Heat & Eat Chicken Fettuccine AlfredoDate of Recall: June 17, 2025
Best By Dates: 06/27/25, 06/26/25 and 06/19/25 or prior
Plant Code Numbers: P-50784, P-47770, and P-47718
Distribution: NationwideIf you still have the product in your fridge or freezer, toss it immediately or return it to your store for a refund.
On June 18, the United States Consumer Product Safety Commission (CPSC) announced that AstroAI, the maker of beloved mini fridges sold at Target, Walmart, and online at Amazon.com, is recalling about 249,100 mini fridges.
The recall follows at least 70 reports of the mini fridges smoking, burning, melting, or catching fire. In two cases, the fires caused more than $360,000 in property damage. The CPSC revealed that the product's electrical switch can short-circuit, which can lead to fires and burns.
The mini fridges sold for about $40 on Amazon and AstroAI.com between June 2019 and June 2022.Product: AstroAI 6-Can Mini Fridge
Date of Recall: June 18, 2025
Model Number: LY0204A
Serial Number: Nine-digit serial number starts with 'S/N' and one of the following numbers: 19, 20, 21, 2201, 2202, or 2203
Dates Sold: Between June 2019 and June 2022If you have a recalled mini fridge, stop using the appliance immediately and contact AstroAI for a free replacement. Take a picture of the recalled appliance, showing the model and serial number. Send this photo to AstroAI at recall@astroai.com or via astroai.com/product-recall.
If you have questions about the recall, contact AstroAI Monday through Friday from 9 a.m. to 5 p.m. PT at 877-278-7624.
On June 13, Meijer announced a recall of Frederik's Dark Chocolate Almonds across six states. The reason? Due to a packaging and processing mix-up, the packages may also contain dark chocolate-covered cashews, which aren't disclosed on the label.
Tree nuts are one of the most common food allergens in the country. Someone with an allergy to cashews could unknowingly eat one and have a serious or life-threatening reaction. As of June 20, Meijer says it hasn't received any reports of illness related to this mix-up.Product: Frederik's Dark Chocolate Almonds in 12-ounce packages
Date of Recall: June 13
Sell By Date: 05/07/2026 or 05/28/2026
UPC Code: 7-08820-68730-1
Distribution: Michigan, Indiana, Illinois, Ohio, Kentucky, and Wisconsin
Product: Frederik's Dark Chocolate Almonds in an 8-count multipack
Date of Recall: June 13
Sell By Date: 05/05/2026
UPC Code: 7-19283-11923-0
Distribution: Michigan, Indiana, Illinois, Ohio, Kentucky, and WisconsinYou can return these items to Meijer for a refund. If you have any other questions, contact Meijer at 800-543-3704 from 7 a.m. to 1 a.m. ET any day of the week.
Read the original article on SIMPLYRECIPES
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
34 minutes ago
- Yahoo
U.S. Supreme Court orders review over religious challenge to New York abortion law
The U.S. Supreme Court on Monday ordered a lower court in New York to reevaluate whether some religious organizations should be excluded from a state mandate that requires employers to provide employee health care plans that include abortion coverage. The ruling from the high court said the case, Diocese of Albany v. Harris, should be sent back to New York courts to be reviewed again in light of an earlier unanimous Wisconsin case related to the Catholic Church groups being denied state tax exemptions. The justices pointed to the Wisconsin case because the New York case poses similar issues about states exempting religious employers and faith-based groups, The Associated Press reported. The New York case stems from a 2017 state mandate that requires health insurance plans provided by employers to include abortion coverage for situations that include rape and incest. The state mandate includes a religious exemption for institutions, but not for religious-affiliated groups. It was challenged by Catholic and Anglican nuns, Catholic dioceses, Christian churches and other faith organizations. They argued the religious exemption is so narrow that it violates the freedom of religion protected under the First Amendment. The most recent order from the Supreme Court is the second time the case has reached the justices after being litigated for years. After the state adopted the mandate in 2017, religious groups challenged it in state court. The appeals court upheld the regulation and the state refused to exempt religious organizations. In 2021, the religious groups appealed the state's ruling to the U.S. Supreme Court. Justices asked New York to reconsider based on its ruling in another case involving religion, Fulton v. Philadelphia. State courts found the Fulton decision was inapplicable to the situation, prompting the groups to bring it to the Supreme Court again. The religious liberty law firm Becket noted in a release that New York's exemption doesn't currently apply to some organizations, including the Carmelite Sisters for the Aged and Infirm and the Teresian Nursing Home because they 'serve the elderly and dying regardless of religious affiliation.' 'New York wants to browbeat nuns into paying for abortions for the great crime of serving all those in need,' Becket Vice President and senior counsel Eric Baxter said in a statement.' Following the Supreme Court's Monday order, the case is headed back to the New York Court of Appeals.
Yahoo
an hour ago
- Yahoo
Ionis (IONS) Announces Leadership Transition as R&D Veteran Richard Geary Prepares to Retire
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) is one of the 10 biotech stocks screaming a buy. On June 12, the company announced the upcoming retirement of Richard Geary, Ph.D., its executive vice president and chief development officer, effective January 2026. Holly Kordasiewicz, Ph.D., currently senior vice president of neurology, will take over the role. Geary has been with Ionis since 1995 and played a pivotal role in bringing six medicines to regulatory approval, including the company's first independently commercialized drug, TRYNGOLZA. A biotechnologist pouring liquid into a test tube and analyzing its components in a lab. Dr. Kordasiewicz, who joined Ionis in 2011, brings over 20 years of experience in R&D, particularly in neurology. She leads the company's neurology program, covering treatments for conditions such as Alzheimer's disease, Angelman syndrome, and Alexander disease. Her work has also contributed to key partnered programs with Biogen, including the development of QALSODY® and IONIS-MAPTRx. As Dr. Geary transitions out of his role, he will continue as a strategic consultant through 2026 to ensure continuity. Ionis leadership praised both Geary's legacy and Kordasiewicz's appointment as a pivotal step in driving the company's commitment to developing transformational therapies for patients with serious diseases. Ionis Pharmaceuticals, Inc. is a U.S.-based commercial-stage biotech company specializing in RNA-targeted therapies. Its approved products include TRYNGOLZA for FCS, WAINUA, and TEGSEDI for ATTRv-PN, SPINRAZA for spinal muscular atrophy, QALSODY for ALS, and WAYLIVRA for rare lipid disorders. The company has a robust pipeline, including late-stage programs like Olezarsen (for hypertriglyceridemia), Donidalorsen (for hereditary angioedema), and Zilganerse (for Alexander disease), along with several mid-stage treatments for neurological and metabolic conditions. Ionis also collaborates with leading pharma firms, including Biogen, GSK, AstraZeneca, Novartis, Roche, and Metagenomi, expanding its reach in developing transformative RNA therapies. While we acknowledge the potential of IONS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 13 Best Software Stocks to Buy Now and 11 Must-Buy AI Stocks Analysts Are Betting On. Disclosure: None.
Yahoo
an hour ago
- Yahoo
Acadia Pharmaceuticals (ACAD) Conducts Inducement Awards to Attract and Retain Top Talent
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) is one of the 10 biotech stocks screaming a buy. On June 17, the company moved to attract and retain top talent by granting inducement awards to 41 employees. Under the 2024 Inducement Plan, the company will award the employees non-qualified stock options of 187,664 shares and 89.582 restricted stock units designed to attract and retain talent. A pharmacist in a pharmacy preparing a prescription medication for a patient suffering from Fibromyalgia. The move to offer inducement awards is part of Acadia Pharmaceuticals' push to secure top-skilled professionals essential for its neuroscience projects. It expects the awards to ensure employees are incentivized to contribute to the long-term objectives expected to lead to sustained growth and innovation. ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) is a biopharma company dedicated to advancing treatments for central nervous system disorders and rare diseases. Its key products include NUPLAZID, approved for Parkinson's disease psychosis, and DAYBUE. While we acknowledge the potential of ACAD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 13 Best Software Stocks to Buy Now and 11 Must-Buy AI Stocks Analysts Are Betting On. Disclosure: None. 擷取數據時發生錯誤 登入存取你的投資組合 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤
